Loading financial data...

ALNYLAM PHARMACEUTICALS, INC. (ALNY) Financial Statements | Global Financial Data

ALNYLAM PHARMACEUTICALS, INC.

ALNYSEC EDGAR

Pharmaceutical PreparationsCIK: 1178670

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$1.8B	$1.0B	$844.3M	—	—
Cost of Goods and Services Sold	$268.2M	$140.2M	$115.0M	$74.2M	$25.1M
Research and Development Expense	$1.0B	$883.0M	$792.2M	$654.8M	$655.1M
Selling, General and Administrative Expense	$795.6M	$770.7M	$620.6M	$588.4M	$479.0M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$282.2M	-$785.1M	-$708.7M	-$828.4M	-$939.4M
Interest Expense	—	—	$143.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$4.2B	$3.8B	$3.5B	$3.6B	$3.4B
Assets, Current	$3.3B	$3.0B	$2.7B	$2.8B	$2.6B
Cash and Cash Equivalents, at Carrying Value	$812.7M	$866.4M	$820.0M	$496.6M	$547.2M
Accounts Receivable, after Allowance for Credit Loss, Current	$405.3M	$327.8M	$238.0M	$198.6M	$102.4M
Inventory, Net	$78.5M	$89.1M	$129.0M	$86.4M	$75.2M
Liabilities	$4.2B	$4.1B	$3.7B	$3.1B	$2.4B
Liabilities, Current	$1.2B	$967.8M	$767.9M	$695.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$104.2M	-$541.3M	-$641.7M	-$615.0M	-$278.4M
Net Cash Provided by (Used in) Investing Activities	-$336.4M	$169.4M	-$273.3M	-$435.5M	-$417.7M
Net Cash Provided by (Used in) Financing Activities	$172.1M	$425.8M	$1.2B	$995.0M	$823.2M
Payments to Acquire Property, Plant, and Equipment	$62.2M	$72.1M	$76.4M	$70.4M	$140.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)